TxCell offers a rare investment opportunity in the regulatory T-cell (Treg) area with major potential in inflammatory and autoimmune disorders. TxCell is restarting the Ovasave Phase IIb study in refractory Crohn’s disease; data is due by early 2018. A flexible CAR Treg platform is being actively developed with a leading academic partner to address possible markets like lupus nephritis and perhaps multiple sclerosis. The indicative value is €7.08/share before further funding of an
31 May 2016
Two valuable and versatile platforms
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Two valuable and versatile platforms
Txcell (TXCL:EPA) | 0 0 -1.3% | Mkt Cap: 29.4m
- Published:
31 May 2016 -
Author:
Dr John Savin -
Pages:
16
TxCell offers a rare investment opportunity in the regulatory T-cell (Treg) area with major potential in inflammatory and autoimmune disorders. TxCell is restarting the Ovasave Phase IIb study in refractory Crohn’s disease; data is due by early 2018. A flexible CAR Treg platform is being actively developed with a leading academic partner to address possible markets like lupus nephritis and perhaps multiple sclerosis. The indicative value is €7.08/share before further funding of an